SideChannel (SDCH) 10-K 14 Jan 14 2012 FY Annual report Financial data

Document_and_Entity_Informatio

Document and Entity Information (USD $)	12 Months Ended
	Sep. 30, 2012	Mar. 30, 2012	Jan. 02, 2014	Jan. 02, 2014
			Common Stock	Preferred Stock
Entity Registrant Name	'NATIONAL SCIENTIFIC CORP/AZ	'	'	'
Entity Central Index Key	'0001022505	'	'	'
Document Type	'10-K	'	'	'
Document Period End Date	30-Sep-12	'	'	'
Amendment Flag	'false	'	'	'
Current Fiscal Year End Date	'--09-30	'	'	'
Is Entity a Well-known Seasoned Issuer?	'No	'	'	'
Is Entity a Voluntary Filer?	'No	'	'	'
Is Entity's Reporting Status Current?	'No	'	'	'
Entity Filer Category	'Smaller Reporting Company	'	'	'
Entity Public Float	'	$1,657,698	'	'
Entity Common Stock, Shares Outstanding	'	'	215,029,216	4,000,000
Document Fiscal Period Focus	'FY	'	'	'
Document Fiscal Year Focus	'2012	'	'	'

Balance_Sheets

Balance Sheets (USD $)	Sep. 30, 2012	Sep. 30, 2011
CURRENT ASSETS:	'	'
Cash	$51,356	$11,016
Accounts receivable	4,888	'
Total current assets	56,244	11,016
Proprietary technology, net	1,022,591	1,200,106
TOTAL ASSETS	1,078,835	1,211,122
CURRENT LIABILITIES:	'	'
Accounts payable and accrued liabilities	229,736	'
Advances from officers	25,591	180,796
Line of credit	21,763	44,535
Net liabilities of discontinued operations	'	1,760,459
Total current liabilities	277,090	1,985,790
Note payable to affiliate	'	1,200,106
TOTAL LIABILITIES	277,090	3,185,896
STOCKHOLDERS' EQUITY (DEFICIT):	'	'
Preferred stock, $0.01 par value, 4,000,000 shares authorized; 4,000,000 issued and outstanding as of September 30, 2012 and 2011	40,000	40,000
Common stock, $0.01 par value, 650,000,000 shares authorized; 211,991,212 and 180,526,879 issued and outstanding as of September 30, 2012 and 2011, respectively	2,119,912	1,805,269
Additional paid-in capital	24,552,924	22,409,927
Accumulated deficit	-25,911,091	-26,229,970
Total stockholders' equity (deficit)	801,745	-1,974,774
TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY (DEFICIT)	$1,078,835	$1,211,122

Balance_Sheets_Parenthetical

Balance Sheets (Parenthetical) (USD $)	Sep. 30, 2012	Sep. 30, 2011
Statement of Financial Position [Abstract]	'	'
Preferred Stock, Par Value	$0.01	$0.01
Preferred Stock, Shares Authorized	4,000,000	4,000,000
Preferred Stock, Shares Issued	4,000,000	4,000,000
Preferred Stock, Shares Outstandng	4,000,000	4,000,000
Common Stock, Par Value	$0.01	$0.01
Common Stock, Shares Authorized	650,000,000	650,000,000
Common Stock, Shares Issued	211,991,212	180,526,879
Common Stock, Shares Outstanding	211,991,212	180,526,879

Statements_of_Operations

Statements of Operations (USD $)	12 Months Ended
	Sep. 30, 2012	Sep. 30, 2011
Income Statement [Abstract]	'	'
REVENUES	$487,703	'
COST OF REVENUES	181,739	'
GROSS PROFIT	305,964	'
OPERATING EXPENSES:	'	'
General and administrative	223,211	246,546
Research and development	151,000	93,871
Impairment of assets	4,000	'
Total operating expenses	378,211	340,417
OPERATING LOSS	-72,247	-340,417
OTHER (INCOME) AND EXPENSES	'	'
Interest expense	1,488	'
Total other (income)	1,488	'
LOSS FROM CONTINUED OPERATIONS	-73,735	-340,417
INCOME (LOSS) FROM DISCONTINUED OPERATIONS	392,614	-16,212
NET INCOME (LOSS)	$318,879	($356,629)
NET INCOME (LOSS) PER COMMON SHARE (Basic and diluted):	'	'
Continuing operations	$0	$0
Discontinued operations	$0	$0
Total	$0	$0
WEIGHTED AVERAGE COMMON SHARES OUTSTANDING	'	'
Basic and diluted	210,463,497	176,559,071

Shareholders_Equity

Shareholders Equity (USD $)	Preferred Stock	Common Stock	Additional Paid-In Capital	Accumulated Deficit	Total
Beginning Balance, Amount at Sep. 30, 2010	'	$1,652,769	$22,434,427	($25,873,341)	($1,786,145)
Beginning Balance, Shares at Sep. 30, 2010	'	165,276,879	'	'	'
Stock issued for settlement of debt, Amount	'	'	'	'	'
Stock issued for purchase of software, Amount	'	'	'	'	'
Stock issued for the purchase of billing software, Amount	'	'	'	'	'
Stock issued for compensation, Shares	4,000,000	15,000,000	'	'	'
Stock issued for compensation, Amount	40,000	150,000	-47,000	'	143,000
Stock issued for cash, Shares	'	250,000	'	'	25,000
Stock issued for cash, Amount	'	2,500	22,500	'	25,000
Write-off of related party debt	'	'	'	'	'
Net loss	'	'	'	-356,629	-356,629
Ending Balance, Amount at Sep. 30, 2011	40,000	1,805,269	22,409,927	-26,229,970	-1,974,774
Ending Balance, Shares at Sep. 30, 2011	4,000,000	180,526,879	'	'	'
Stock issued for settlement of debt, Shares	'	30,000,000	'	'	30,000,000
Stock issued for settlement of debt, Amount	'	300,000	900,106	'	1,200,106
Stock issued for investment, Shares	'	200,000	'	'	'
Stock issued for investment, Amount	'	2,000	2,000	'	4,000
Stock issued for purchase of software, Shares	'	100,000	'	'	100,000
Stock issued for purchase of software, Amount	'	1,000	1,500	'	2,500
Stock issued for the purchase of billing software, Shares	'	941,333	'	'	'
Stock issued for the purchase of billing software, Amount	'	9,413	9,888	'	19,301
Stock issued for consulting services, Shares	'	33,000	'	'	'
Stock issued for consulting services, Amount	'	330	294	'	624
Stock issued for compensation, Amount	'	'	'	'	624
Stock issued for cash, Shares	'	190,000	'	'	68,000
Stock issued for cash, Amount	'	1,900	66,100	'	68,000
Write-off of related party debt	'	'	1,163,109	'	1,163,109
Net loss	'	'	'	318,879	318,879
Ending Balance, Amount at Sep. 30, 2012	$40,000	$2,119,912	$24,552,924	($25,911,091)	$801,745
Ending Balance, Shares at Sep. 30, 2012	4,000,000	211,991,212	'	'	200,000

Statements_of_Cash_Flows

Statements of Cash Flows (USD $)	12 Months Ended
	Sep. 30, 2012	Sep. 30, 2011
Statement of Cash Flows [Abstract]	'	'
Net income (loss)	$318,879	($356,629)
Discontinued operations	-392,614	16,212
Net loss from continuing operations	-73,735	-340,417
Adjustments to reconcile net income (loss) from continuing operations to net cash from operating activities:	'	'
Depreciation and amortization	180,015	'
Impairment of assets	4,000	'
Stock issued for compensation	624	143,000
Stock issued with licensing agreements	19,301	'
Changes in operating assets and liabilities:	'	'
Accounts receivable	-4,888	'
Accrued expenses	25,000	'
Net assets and liabilities from discontinued operations	'	-23,214
Net cash provided by (used in) operating activities	150,317	-220,631
CASH FLOWS FROM FINANCING ACTIVITIES:	'	'
Common stock issued for cash	68,000	25,000
Advances from officer	7,969	159,515
Repayment of advances from officer	-188,410	'
Proceeds from line of credit	2,464	44,535
Net cash (used in) provided by financing activities	-109,977	229,050
INCREASE IN CASH	40,340	8,419
CASH, BEGINNING OF YEAR	11,016	2,597
CASH, END OF YEAR	51,356	11,016
CASH PAID FOR:	'	'
Interest	'	'
Taxes	'	'
SUPPLEMENTAL DISCLOSURE OF NONCASH OPERATING AND FINANCING ACTIVITIES:	'	'
Reclass from discontinued operation to accounts payable	204,736	'
Write off of debt - related parties	1,163,109	'
Common stock issued for purchase of software	2,500	'
Transfer from line of credit to advance from officer	25,236	'
Common stock issued for settlement of debt	1,200,106	'
Debt issued for purchase of proprietary technology	'	$1,200,106

NOTE_1_DESCRIPTION_OF_BUSINESS

NOTE 1. DESCRIPTION OF BUSINESS	12 Months Ended
	Sep. 30, 2012
Accounting Policies [Abstract]	'
NOTE 1. DESCRIPTION OF BUSINESS	'
	NOTE 1 - DESCRIPTION OF BUSINESS
	Cloud Medical Doctor Software Corporation (the “Company”) was incorporated in Texas on June 22, 1953 as American Mortgage Company. On May 16, 1996, the Company changed its name to National Scientific Corporation. On April 3, 2012, the Company changed its name to Cloud Medical Doctor Software Corporation.
	In 2011, Cloud-MD introduced the Cloud-MD Office, a “Cloud Based”, 5010 ready and ICD-10 compliant, fully integrated and interoperable suite of medical software and services, designed by experienced healthcare analysts and programmers for healthcare providers, that produces “Actionable Information” to help Independent Physician Practices, New Care Delivery Models (ACO), Healthcare Systems and Billing Services optimize a wide range of business processes resulting in Increased Profits, Higher Quality, Greater Efficiency, Noticeable Cost Reductions and Better Patient Care. Current software product offerings include Practice Management, Electronic Medical Records, Revenue Management, Patient Financial Solutions, Medical and Pharmaceutical Supply Management, Claims Management and PHI Exchange.
	In 2012 Cloud-MD launched Cloud-MD Billing Services which provides management of medical claims from posting physician charges and payments into our medical billing software. The software uses a continuous insurance claim follow-up system to track and research all rejected or denied medical claims; a Comprehensive Reporting module that includes monthly financial statements sent to our clients so they can see how their practice is performing and a variety of detailed reports giving our clients the necessary information and tools used to assist in the increased production which leads to more profit; and patient account inquiries & support to assist patients with their billing and insurance questions.

NOTE_2_BASIS_OF_PRESENTATION

NOTE 2. BASIS OF PRESENTATION	12 Months Ended
	Sep. 30, 2012
Organization, Consolidation and Presentation of Financial Statements [Abstract]	'
NOTE 2. BASIS OF PRESENTATION	'
	NOTE 2 - BASIS OF PRESENTATION
	The preparation of financial statements in conformity with accounting principles generally accepted in the United States (“GAAP”) requires management to make estimates and assumptions that affect (i) the reported amounts of assets and liabilities, (ii) the disclosure of contingent assets and liabilities known to exist as of the date the financial statements are published, and (iii) the reported amount of net revenues and expenses recognized during the periods presented. Adjustments made with respect to the use of estimates often relate to improved information not previously available. Uncertainties with respect to such estimates and assumptions are inherent in the preparation of financial statements; accordingly, actual results could differ from these estimates.
	In managements’ opinion, all adjustments (consisting of normal recurring accruals) considered necessary for a fair presentation have been included.

NOTE_3_GOING_CONCERN_ISSUES

NOTE 3. GOING CONCERN ISSUES	12 Months Ended
	Sep. 30, 2012
Organization, Consolidation and Presentation of Financial Statements [Abstract]	'
NOTE 3. GOING CONCERN ISSUES	'
	NOTE 3 - GOING CONCERN ISSUES
	The accompanying financial statements have been prepared in conformity with accounting principles generally accepted in the United States of America, which contemplate continuation of the Company as a going concern. However, the Company has an accumulated deficit at September 30, 2012 of $25,911,091 and needs additional cash to maintain its operations.
	These factors raise doubt about the Company’s ability to continue as a going concern. The accompanying financial statements do not include any adjustments that might result from the outcome of this uncertainty. The Company’s continued existence is dependent upon management’s ability to develop profitable operations, continued contributions from the Company’s executive officers to finance its operations and the ability to obtain additional funding sources to explore potential strategic relationships and to provide capital and other resources for the further development and marketing of the Company’s products and business.

NOTE_4_SUMMARY_OF_SIGNIFICANT_

NOTE 4. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES	12 Months Ended
	Sep. 30, 2012
Accounting Policies [Abstract]	'
NOTE 4. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES	'
	NOTE 4 – SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES
	The Company prepares its financial statements in accordance with accounting principles generally accepted in the United States of America. Significant accounting policies are as follows:
	Use of Estimates and Assumptions
	The preparation of financial statements in conformity with accounting principles generally accepted in the United States (“GAAP”) requires management to make estimates and assumptions that affect (i) the reported amounts of assets and liabilities, (ii) the disclosure of contingent assets and liabilities known to exist as of the date the financial statements are published, and (iii) the reported amount of net revenues and expenses recognized during the periods presented. Adjustments made with respect to the use of estimates often relate to improved information not previously available. Uncertainties with respect to such estimates and assumptions are inherent in the preparation of financial statements; accordingly, actual results could differ from these estimates. The Company’s most significant estimates relate to the valuation of its proprietary technology and its valuation of its common stock.
	Cash and Cash Equivalents
	The Company considers all highly liquid investments with an original maturity of three months or less to be cash equivalents.  At September 30, 2012, cash and cash equivalents include cash on hand and cash in the bank and the FDIC insures these deposits up to $250,000.
	Impairment of Long-Lived Assets
	The long-lived assets were being evaluated for impairment whenever events or changes in business circumstances indicate that the carrying amount of the assets may not be fully recoverable or that the useful lives of these assets are no longer appropriate. Each impairment test is based on a comparison of the undiscounted future cash flows to the recorded value of the asset. If impairment is indicated, the asset is written down to its estimated fair value. The identifiable intangibles are amortized over their useful lives of 5 years and are reviewed annually for impairment. The Company impaired $4,000 directly related to the acquisition of Doctors Network of America operating in Jackson Mississippi, which is presently in litigation.
	Fair Value of Financial Instruments
	The Company's financial instruments consist primarily of cash, accounts payable and accrued expenses, and debt. The carrying amounts of such financial instruments approximate their respective estimated fair value due to the short-term maturities and approximate market interest rates of these instruments.
	The Company adopted ASC Topic 820, Fair Value Measurements (“ASC Topic 820”), which defines fair value, establishes a framework for measuring fair value, and expands disclosures about fair value measurements.  The standard provides a consistent definition of fair value which focuses on an exit price that would be received upon sale of an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date.  The standard also prioritizes, within the measurement of fair value, the use of market-based information over entity specific information and establishes a three-level hierarchy for fair value measurements based on the nature of inputs used in the valuation of an asset or liability as of the measurement date.
	The three-level hierarchy for fair value measurements is defined as follows:
	•	Level 1 – inputs to the valuation methodology are quoted prices (unadjusted) for identical assets or liabilities in active markets; liabilities in active markets;
	•	Level 2 – inputs to the valuation methodology include quoted prices for similar assets and liabilities in active markets, and inputs that are observable for the asset or liability other than quoted prices, either directly or indirectly, including inputs in markets that are not considered to be active; or directly or indirectly including inputs in markets that are not considered to be active;
	•	Level 3 – inputs to the valuation methodology are unobservable and significant to the fair value measurement
	The following table summarizes fair value measurements by level at September 30, 2012 and 2011 for assets measured at fair value on a recurring basis:
		Level 1	Level 2	Level 3		Total
	At September 30, 2012
	Proprietary Technology				1,022,591		1,022,591
	Total Proprietary Technology				1,022,591		1,022,591
	At September 30, 2011
	Proprietary Technology				1,200,106		1,200,106
	Total Proprietary Technology				1,200,106		1,200,106
	Accounts Receivable and Allowance for Uncollectible Accounts
	Substantially all of the Company’s accounts receivable balance is related to trade receivables. Trade accounts receivable are recorded at the invoiced amount and do not bear interest. The allowance for doubtful accounts is the Company’s best estimate of the amount of probable credit losses in its existing accounts receivable. The Company will maintain allowances for doubtful accounts for estimated losses resulting from the inability of its customers to make required payments for services. Accounts with known financial issues are first reviewed and specific estimates are recorded. The remaining accounts receivable balances are then grouped in categories by the number of days the balance is past due, and the estimated loss is calculated as a percentage of the total category based upon past history. Account balances are charged against the allowance when it is probable the receivable will not be recovered. As of September 30, 2012 and 2011, the Company had no valuation allowance for the Company’s accounts receivable.
	Income Taxes
	The Company utilizes the asset and liability method in accounting for income taxes. Under this method, deferred tax assets and liabilities are recognized for operating loss and tax credit carry-forwards and for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the year in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in the results of operations in the period that includes the enactment date. A valuation allowance is recorded to reduce the carrying amounts of deferred tax assets unless it is more likely than not that the value of such assets will be realized.
	The Company uses the two-step approach to recognizing and measuring uncertain tax positions. The first step is to evaluate the tax position for recognition by determining if the weight of available evidence indicates it is more likely than not, that the position will be sustained on audit, including resolution of related appeals or litigation processes, if any. The second step is to measure the tax benefit as the largest amount, which is more than 50% likely of being realized upon ultimate settlement. The Company considers many factors when evaluating and estimating the Company's tax positions and tax benefits, which may require periodic adjustments. At September 30, 2012, the Company did not record any liabilities for uncertain tax positions.
	Revenue Recognition
	License revenue consists principally of revenue earned under software license agreements. The Company sells its software to a medical practitioner for direct payment or through a third party leasing company for direct payment to the Company. The third party lease agreement is a non-recourse debt and the Company is not responsible for the default of the medical practitioner. License revenue is generally recognized when a signed contract or other persuasive evidence of an arrangement exists, the software has been electronically delivered, the license fee is fixed or is measured on a paid user basis; and collection of the resulting receivable is probable. When contracts contain multiple elements wherein Vendor-Specific Objective Evidence (“VSOE”) exists for all undelivered elements, we account for the delivered elements in accordance with the “Residual Method.” VSOE of fair value for maintenance and support is established by a stated renewal rate, if substantive, included in the license arrangement or rates charged in stand-alone sales of maintenance and support. Revenue from subscription license agreements, which include software, rights to unspecified future products and maintenance, is recognized ratably over the term of the subscription period.
	Provided all other revenue criteria are met, the upfront, minimum, non-refundable license fees from customers are generally recognized upon delivery and on-going royalty fees are generally recognized upon reports of new licenses issued. If there is significant uncertainty about the project completion or receipt of payment for professional services, revenue is deferred until the uncertainty is sufficiently resolved. VSOE of fair value of services is based upon stand-alone sales of those services.
	Subscription revenue is generated from bandwidth and information storage. One year and each year thereafter the software is purchased and installed the purchaser will pay an annual fee of $1,200, $1,500, $1,800, and $2,400, respectively. Subscription revenue is recognized ratably over the term of the agreement.
	Transaction revenue is generated from the following services and recognized when transaction occurs:
	·	Electronic Remittance Advise $0.35 Electronic remittance transaction fee;
	·	Paper Claims $1.00 Paper claim fee;
	·	Carrier Direct $0.16 Carrier direct fee;
	·	Fast Forward $0.35 Fast forward transaction fee; and,
	·	Patient Credit $2.50 Automatic Debit processing per transaction paid by the patient
	The Company has not incurred any transaction revenues in the year ended September 30, 2012.
	Cost of License, and Subscriptions Revenues
	Cost of license revenue is primarily comprised of the license-based royalties to third parties and production and distribution costs for initial product licenses.
	Cost of subscription revenue is primarily comprised of the costs associated with the customer support personnel that provide maintenance, enhancement and support services to customers.
	The amortization of acquired technology for products acquired through business combinations are considered as the cost of revenues.
	Sales Commissions
	The Company pays commissions, including sales bonuses, to the direct sales force related to revenue transactions under sales compensation plans established annually. The commission payments are typically paid in full in the month or quarter following execution of the customer contracts. The Company paid commissions of $73,298 and $0 for the years ended September 30, 2012 and 2011, respectively.
	Research and Development and Software Development Costs
	Capitalization of certain software development costs subsequent to the establishment of technological feasibility. Based on our product development process, technological feasibility is established upon the completion of a working model. To date, costs incurred by us from the completion of the working model to the point at which the product is ready for general release have been insignificant. Accordingly, we have charged all such costs to research and development expense in the period incurred. Our research and development costs for the years ended September 30, 2012 and 2011 were $151,000 and $93,871, respectively.
	Share-Based Compensation
	The Company measures the cost of services received in exchange for an award of an equity instrument based on the grant-date fair value of the award.  Compensation cost is recognized over the vesting or requisite service period.
	Basic and Diluted Net Loss per Common Share
	Basic income (loss) per share is computed by dividing net income (loss) available to common shareholders by the weighted average number of common shares outstanding during the reporting period. The weighted average number of shares is calculated by taking the number of shares outstanding and weighting them by the amount of time that they were outstanding.  Diluted earnings per share reflects the potential dilution that could occur if stock options, warrants, and other commitments to issue common stock were exercised or equity awards vest resulting in the issuance of common stock that could share in the earnings of the Company. As of September 30, 2012 and 2011, the Company had no potentially dilutive instruments outstanding.
	Diluted loss per share is the same as basic loss per share during periods where net losses are incurred since the inclusion of the potential common stock equivalents would be anti-dilutive as a result of the net loss.
	Concentration of Credit Risk
	All of the Company’s cash and cash equivalents are maintained in regional and national financial institutions. The Company has exposure to credit risk to the extent that its cash and cash equivalents exceed amounts covered by the U.S. federal deposit insurance; however, the Company has not experienced any losses in such accounts. In management’s opinion, the capitalization and operating history of the financial institutions are such that the likelihood of material loss is remote.
	Reclassifications
	Certain prior period amounts have been reclassified to conform to the current year presentation.
	Subsequent Events
	The Company has evaluated all transactions occurring between the end of its fiscal year, September 30, 2012, through the date of issuance of the financial statements for subsequent event disclosure consideration.
	Recent Accounting Pronouncements
	No accounting standards or interpretations issued recently are expected to a have a material impact on the Company’s financial position, operations or cash flows.

NOTE_5_INTANGIBLE_ASSETS

NOTE 5. INTANGIBLE ASSETS	12 Months Ended
	Sep. 30, 2012
Goodwill and Intangible Assets Disclosure [Abstract]	'
NOTE 5. INTANGIBLE ASSETS	'
	NOTE 5 – INTANGIBLE ASSETS
	The following is a detail of intangible assets at September 30, 2012 and 2011:
		2012			2011
	Source Code License	$	2,500		$	—
	Software License		1,200,106			1,200,106
	Acquisition of Doctor’s Network of America		4,000			—
	Total intangible assets		1,202,606			1,200,106
	Accumulated amortization of intangible assets		(180,015	)		—
	Impairment of assets		(4,000	)		—
	Total intangible assets	$	1,022,591		$	1,200,106
	The Company recognized a $4,000 impairment of long-lived assets as of September 30, 2012. The Company’s intangible assets were placed into service starting in the second quarter of fiscal 2012. The amortization expense was $180,015 and $0 for the years ended September 30, 2012 and 2011, respectively.
	Source Code License
	On August 14, 2012, the Company, through a comprehensive agreement (the “License Agreement”) with MediSouth, LLC, (“MediSouth”) has purchased a complete source code license (the “License”) and will integrate and enhance this feature set as part of its ever expanding Cloud-MD Office product suite.
	The License Agreement requires the following:
	a)	That MediSouth will provide the Company with all software updates for the License within 5 working days of MediSouth implementing those same software updates in its own production version of the License.
	b)	The Company has the right to modify the software contained in the License to meet its operational needs.
	c)	The Company shall provide to MediSouth, with the permission of each affected Company client, the de-identified purchasing data which is any data that would identify a patient such as social security numbers, date of birth, health condition, among others that it collects as a result of the Company’s clients utilizing the embedded Medical Supplies and Pharmaceutical Inventory Management functionality provided by the License.
	e)	MediSouth shall receive 100,000 shares of the Company’s non-dilutable, common stock with a one (1) year trading restriction.
	f)	The Company may not sell the License, transfer the License, allow any other entity to use the License as part of that entity's software application or transfer any rights to another party to use the License separately from the Company’s products in which the License is embedded.
	The fair value of the consideration and the assets acquired is based on the aggregate value of the 100,000 shares of common stock issued in exchange for the software. The total fair value on August 14, 2012 was $2,500.
	Software License
	On January 2, 2011, the Company entered into an asset purchase agreement with certain private companies owned by Michael de la Garza (“MDLG”), the Company’s CEO, whereby the Company acquired the rights to proprietary medical billing and practice management software developed by the private companies.
	The Company issued a $1,200,106 convertible promissory note with an 8% interest rate and convertible into common stock of the Company at a price to be determined later in exchange for the purchase of the software. The note matures on April 30, 2021.
	In October 2011, the Company issued Absolute Medical Software Systems, LLC an entity owned by MDLG, 30,000,000 shares of common stock in full payment of this promissory note and interest accrued as of the date of conversion. The market price per share on the date of grant was $0.008 per share. No gain or loss was recorded on the conversion of the convertible promissory note
	The Company has determined that due to the voting rights of the Preferred A shares owned by MDLG, that the transaction occurred between parties under common control. Accordingly, the Company has determined that the cost basis of the software acquired should become the cost basis of the Company.
	Cost Basis for assets acquired  under Common Control	Cost Basis
	Cost basis of Consideration:
	Absolute Medical Software Systems LLC development costs from inception	$	1,011,222
	Impairment of software on September 10, 2008 to value		-11,222
	Total Value at September 10, 2008	$	1,000,000
	Software Update to Operate on Cloud Based Platform
	Absolute Medical Software Systems LLC development costs	$	200,106
	Total Cost Basis at January 1, 2011	$	1,200,106
	Doctors Network of America
	On June 22, 2012 the Company entered into an acquisition agreement that ultimately closed on March 16, 2013. The Company agreed to acquire Doctors Network of America in Flowood, Mississippi for 500,000 shares of common stock. As of September 30, 2012, only 200,000 shares were issued as a deposit. The value of the shares on the date of grant was $4,000 which was recorded as a deposit on acquisition. Immediately after the transaction was closed on March 15, 2013, the sellers refused to pay for medical billing process transaction fees in accordance with their contracts which was approximately $200,000. The Company and the sellers are currently in litigation over the disputed transaction fees. Accordingly, as of September 30, 2012, the Company has impaired the full value of the deposit.

NOTE_6_DISCONTINUED_OPERATIONS

NOTE 6. DISCONTINUED OPERATIONS	12 Months Ended
	Sep. 30, 2012
Discontinued Operations and Disposal Groups [Abstract]	'
NOTE 6. DISCONTINUED OPERATIONS	'
	NOTE 6- DISCONTINUED OPERATIONS
	The Company discontinued the Mobile DVR and Location Products on February 4, 2010. The product required that most of our customers require monitoring and/or tracking of a person or object, and reporting this information back to a central location. The product was primarily used in school systems to track students boarding and exiting school buses for the safety of the students.
	The Company’s former Board of Directors believed that it was in the best interest of the Company to discontinue the business operations of the GPS operational device business. In 2011, this business was transferred to National Scientific, LLC, a company owned by the Company’s prior CEO, by prior management in which the Company’s former CEO was to pay $100,000 for that technology. The former officer never paid the required compensation. The Company’s new management recorded the activities associated with the transferred assets as discontinued operations.
	Accordingly, the Company reclassified the assets, liabilities and operations related to its GPS operational device business as discontinued operations.  Consequently, the accompanying financial statements reflect the assets, liabilities and operations of the GPS operational device business as net assets of discontinued operations, net liabilities of discontinued operations and operations from discontinued operations. As of September 30, 2012 and 2011, the Company did not have any net assets related to the GPS operational device business.
	Details of the classifications for net liabilities and operations are shown below.
		30-Sep-12			September 30,
					2011
	Net liabilities of discontinued operations:
	Accounts payable and accrued expenses	$	—		$	169,176
	Disputed salaries & vacation of former officers		—			968,645
	Disputed salary – former employee		—			20,256
	Disputed payroll taxes for back pay of former officers		—			84,701
	Disputed interest		—			209,215
	Interest expenses		—			42,137
	Former officer note payable at 8% interest rate		—			59,704
	Shareholders demand note payable at 12%		—			11,625
	Shareholders demand note payable at 12%		—			20,000
	Unsecured note payable at 8% interest due November 2010 interest payments in default at 9/30/2009		—			175,000
	Net liabilities of discontinued operations	$	—		$	1,760,459
		Year ended
		September 30,
		2012			2011
	Discontinued operations:
	Revenues	$	—		$	3,400
	Cost of sales		—			—
	Operating expenses		—			—
	Interest expense		(17,868	)		(19,612	)
	Gain from write-off of debt		410,482			—
	Gain (Loss) from Discontinued Operations	$	392,614		$	(16,212	)
	Commitments and contingencies that were discontinued as a result of the transfer of the assets to National Scientific LLC as follows:
	On November 1, 2005, the Company entered into a financing program with Strategic Working Capital Fund, LP. The terms of this program included a five-year note payable at maturity in November 2010 for $175,000, at an annual interest rate of 8%. Interest was due and payable semi-annually on May 1st and November 1st for each year in which the note is outstanding The transaction also included 1,200,000 restricted common shares and a conversion/exchange option to convert the principal amount and any unpaid interest of the Note into common shares at a per share conversion price of $0.0525. These shares included weighted average anti-dilution provisions, as well as piggyback registration rights. Additionally, the note had various put and call rights, and has a right to early payment under certain conditions after 2 years. The 1,200,000 restricted common shares were recorded at $0.043, which was the five-day average market closing price of our stock. The note and common stock were issued with a debt discount of $51,600 and a beneficial conversion feature of $9,933. The discount and beneficial conversion feature are being amortized to interest expense over the term of the note, which is approximately 60 months. The issuance of the shares resulted in deferred financing costs of $24,000. The deferred financing costs were amortized over term of the note, which is approximately 60 months, and are included in the statement of operations as offering costs. Management received a legal opinion and determined that this note is unenforceable and has been written off during fiscal year ended September 30, 2012 (See Note 7 – Debt Mitigation Program).
	On February 24, 2005, March 28, 2005, May 2, 2005, and May 27, 2005 the Company’s former Chairman Michael Grollman made personal loans to the Company totaling $159,000 to assist it with working capital needs. The loans are evidenced by a demand note that provides for repayment within five business days of a demand notice from Mr. Grollman, with interest of 6% compounded annually from June 1, 2005. These loans were secured by an interest in the copyrights in the Company’s iBus software and designs.  During the three months ended September 30, 2007, these loans were paid down by $11,000. As of September 30, 2007, these loans had a balance outstanding of $148,000 and the interest rate going forward was adjusted to 8% compounded annually from October 1, 2007.  On September 30, 2007, the Company converted unpaid interest of $13,300 of demand notes payable to Michael Grollman into a new demand note of $13,300 that provided for repayment within five business days of a demand notice from Mr. Grollman, with interest of 8% compounded annually on October 1st. Management received a legal opinion and determined this note is unenforceable and has been written off during fiscal year ended September 30, 2012 (See Note 7 – Debt Mitigation Program).
	On April 27, 2006, the Company secured a short-term loan of $16,625 from a shareholder. The loan carries an origination/placement fee of $500 and has a perfectible security interest a) prior to delivery in any assets purchased for the fulfillment of a customer’s order dated March 16, 2006, and b) in any receivable resulting from the fulfillment of the customer’s purchase order. The interest rate on the loan was 12%. The transaction also included 100,000 warrants to purchase our common stock at $0.036 at any time before April 27, 2009 which have expired unexercised. The note had an approximate maturity date of June 15, 2006. Management received a legal opinion and determined this note is unenforceable and has been written off during fiscal year ended September 30, 2012 (See Note 7 – Debt Mitigation Program).
	On May 31, 2006, we secured a short-term loan of $20,000 from a shareholder. The loan carried an origination/placement fee of $500 and has a perfectible security interest a) prior to delivery in any assets purchased for the fulfillment of Clover Park, WA’s order and b) in any receivable resulting from the fulfillment of the Clover Park purchase order. The interest rate on the loan was 12%. The transaction also included 100,000 warrants to purchase our common stock at $0.036 at any time before May 31, 2009 which expired unexercised. The note had a maturity date of July 10, 2006. Management received a legal opinion and determined this note is unenforceable and has been written off during fiscal year ended September 30, 2012 (See Note 7 – Debt Mitigation Program).

NOTE_7_DEBT_MITIGATION_PROGRAM

NOTE 7. DEBT MITIGATION PROGRAM	12 Months Ended
	Sep. 30, 2012
OTHER (INCOME) AND EXPENSES	'
NOTE 7. DEBT MITIGATION PROGRAM	'
	NOTE 7 – DEBT MITIGATION PROGRAM
	The Company determined that the statute of limitations for certain of the Company’s creditors to enforce collection of any amounts they might be owed has now elapsed. Based on the determinations and findings, during the year ended September 30, 2012, the Company wrote off $1,573,591 in creditor liabilities which were all previously included in current liabilities in the accompanying balance sheet. As a result of this write-off, the Company recognized a gain on the write off of liabilities in the amount of $410,482 for third party liabilities, which was recorded in discontinued operations, and additional paid-in capital of $1,163,109 for related party liabilities. The Company will continue to conduct this analysis going forward and write off obligations when such obligations are no longer enforceable based on applicable law.
	The following liabilities, through the opinion of legal counsel, were determined by the Company as unenforceable.
			30-Sep-12
	Debt Mitigation Program:
	Accounts payable and accrued expenses	$	66,281
	Disputed salaries & vacation of former officers		968,645
	Disputed salary – former employee		20,256
	Disputed payroll taxes for back pay of former officers		84,701
	Disputed interest		227,083
	Shareholders demand note payable at 12%		11,625
	Shareholders demand note payable at 12%		20,000
	Unsecured note payable at 8% interest due in November 2010, interest payments in default		175,000
	Total debt mitigation program	$	1,573,591
	Gain on write off of debt	$	(410,483	)
	Additional paid-in capital (1)	$	(1,163,108	)
	-1	All amounts that were owed to related parties in prior years were recorded to paid-in-capital.

NOTE_8_COMMITMENT_AND_CONTINGE

NOTE 8. COMMITMENT AND CONTINGENCIES	12 Months Ended
	Sep. 30, 2012
COMMITMENTS AND CONTINGENCIES	'
NOTE 8. COMMITMENT AND CONTINGENCIES	'
	NOTE 8– COMMITMENT AND CONTINGENCIES
	Rent expense for the years ended September 30, 2012 and 2011 was $0 for both years.
	The Company entered into an agreement to purchase the assets of Doctors Network of America in June of 2012 and after due diligence by both parties the transaction closed on March 15, 2013. Immediately after the transaction was closed on March 15, 2013, the sellers refused to pay for medical billing process transaction fees in accordance with their contracts which was approximately $200,000. In June 2013, the Company sued the sellers in federal court for breach of contract among other causes of action of unpaid medical billing transaction fees of nearly $200,000. The Company believes it will be successful in its litigation. However, if the Company is successful, the collectability of the judgment is highly questionable.
	The Company has issued shares to new investors since January 2, 2011, that have an anti-reverse common stock split clause if the Company reverses the common stock. The reverse split of common stock is determined by management but must be approved by Financial Industry Regulation Authority (“FINRA”). Presently FINRA has denied the Company the right to reverse split the common stock until all Securities and Exchange Commission filings are current and at that point and time the Company will submit a request to FINRA to execute a reverse split of the common stock of the Company. The current investors holding anti-reverse split stock will allow them to hold the same number of shares of common stock as status quo after the reverse split. The anti-reverse split common stock is only for stock subject to reverse split and once the reverse split is completed the stock the shareholders that received anti-reverse split stock will be held with regular stockholders as the Company proceeds forward. In accordance with the anti-reverse split provision, no further shares will be issued to the anti-reverse split shareholders once the reverse split is approved and completed.
	As discussed in Note 7, the Company has written off $1,573,591 in accounts payable, accrued liabilities and notes payable based on the opinion of legal counsel. However, the related creditors could make a claim in the future in regards to these liabilities.

NOTE_9_RELATED_PARTY_TRANSACTI

NOTE 9. RELATED PARTY TRANSACTIONS	12 Months Ended
	Sep. 30, 2012
Related Party Transactions [Abstract]	'
NOTE 9. RELATED PARTY TRANSACTIONS	'
	NOTE 9– RELATED PARTY TRANSACTIONS
	During the year ended September 30, 2011, the Company issued 15,000,000 common shares to new management at the trading price of the common stock of $0.007. The stock was recorded at fair value as compensation expense of $105,000.
	In April 2011, the Company issued 4,000,000 common shares to new management valued at the trading price of the common stock of $0.0095. The stock was recorded at fair value as compensation expense of $38,000.
	On October 15, 2013, the Company issued 30,000,000 common shares to the CEO to convert the debt in the principal amount of $1,200,106 in principal.
	During the years ended September 30, 2012 and 2011, the CEO advanced the Company cash proceeds of $7,969 and $159,515, respectively. In addition, during the year ended September 30, 2012, the CEO made payments on the Company’s behalf of $25,236 on the Company’s line of credit. The Company repaid $188,410 and $0 of the advances in the years ended September 30, 2012 and 2011, respectively. The advances from the CEO are due on demand and do not accrue interest. As of September 30, 2012 and 2011, the amount owed to the CEO for advances was $25,591 and $180,796, respectively.

NOTE_10_EQUITY

NOTE 10. EQUITY	12 Months Ended
	Sep. 30, 2012
Equity [Abstract]	'
NOTE 10. EQUITY	'
	NOTE 10 - EQUITY
	On April 11, 2011, the Company amended its Articles of Incorporation to increase the authorized common shares to 650,000,000 shares and 4,000,000 preferred shares at a par value of $0.01.
	Fiscal Year Ended September 30, 2012
	During year ended September 30, 2012, the Company issued 190,000 shares of common stock for $68,000 as follows:
	Date		Number of Shares		Value
		15-Oct-11		25,000	$	5,000
		29-Dec-11		100,000	$	50,000
		21-Jun-12		65,000	$	13,000
	On October 15, 2011, the Company issued 30,000,000 shares of common stock for the conversion of debt from our CEO in the principal amount of $1,200,106.
	December 15, 2011, the Company issued 18,000 shares of common stock for services rendered by professionals and recorded expense based upon the market price of $0.0102 and expensed $184 as consulting fees.
	The Company issued 941,333 shares of common stock to third parties that have purchased our medical billing software at the market price of the common stock ranging from $0.0115 to $0.03. The Company recorded $19,301 as a reduction to revenue for the value of the shares issued.
	The Company issued 200,000 shares of common stock on June 21, 2012 to Krooss Medical Management in accordance with the acquisition agreement for Doctors Network of America and recorded it at the market price of the common shares of $0.020 and as an investment in Krooss Medical Management of $4,000.
	On June 21, 2012, the Company issued 1,000 shares of common stock for services rendered by professionals and recorded expense based upon the market price of $0.02 and expensed $20 as consulting fees.
	The Company issued 100,000 shares of common stock to MediSouth LLC in accordance with the acquisition agreement and recorded it at the market price of the common shares of $0.025 and as an investment in MediSouth LLC of $2,500.
	On September 9, 2012, the Company issued 14,000 shares of common stock for services rendered by professionals and recorded expense based upon the market price of $0.03 and expensed $420 as consulting fees.
	Fiscal Year Ended September 30, 2011
	On January 2, 2011, the Company issued 15,000,000 shares of common stock to new management, valued at the market price of the common stock of $0.007 on the date of grant. The shares were recorded as compensation expense of $105,000.
	On September 12, 2011, the Company sold 250,000 shares of common stock for $25,000 in net cash proceeds.
	Preferred Stock
	The Company has authorized 4,000,000 shares of preferred stock, at $0.01 par value. The Corporation established and designates the rights and preferences of a Series A Preferred Stock, and reserve 4,000,000 shares of preferred stock against its issuance, such rights, preferences and designations. Each share of the Preferred Stock has 150 votes on all matters presented to be voted by the holders of our common stock. All 4,000,000 shares of preferred stock have been issued to our CEO & CFO on April 11, 2011, valued at the trading price of the common stock of $0.0095 and were recorded as an expense of $38,000.

NOTE_11_STOCKBASED_COMPENSATIO

NOTE 11. STOCK-BASED COMPENSATION	12 Months Ended
	Sep. 30, 2012
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]	'
NOTE 11. STOCK-BASED COMPENSATION	'
	NOTE 11 – STOCK-BASED COMPENSATION
	Options
	The Prior board of directors adopted the 2000 Stock Option Plan effective January 1, 2001. Our stockholders formally approved the 2000 Stock Option Plan on February 14, 2001. The 2000 Stock Option plan terminated in accordance with the plan provisions on December 1, 2010. The current Board of Directors did not extend the Stock Option Plan, allowing it to terminate.
	There were no options outstanding for the years ended September 30, 2012 and 2011, respectively.
	Warrants
	The Company values all warrants using the Black-Scholes option-pricing model.  Critical assumptions for the Black-Scholes option-pricing model include the market value of the stock price at the time of issuance, the risk-free interest rate corresponding to the term of the warrant, the volatility of the Company’s stock price, dividend yield on the common stock, as well as the exercise price and term of the warrant.  The warrants are not subject to any form of vesting schedule and, therefore, are exercisable by the holders anytime at their discretion during the life of the warrant.  No discounts were applied to the valuation determined by the Black-Scholes option-pricing model.
	During the years ended September 30, 2012 and 2011, no awards were granted, no share purchase warrants were exercised, and no warrants were forfeited.
	Summary of warrant activity for the years ended September 30, 2012 and 2011 is presented below:
			Number of			Weighted		Weighted Average		Aggregate
			Shares Granted			Average		Remaining		Intrinsic Value
						Exercise Price		Contractual Life
								(years)
		30-Sep-10		2,308,497		$	0.1		0.38		—
		Grants		—			—
		Expired		(2,308,497	)		—
		30-Sep-11		—		$	—	$	—	$	—
		Grants		—
		Expired		—
		30-Sep-12		—		$	—	$	—	$	—

NOTE_12_INCOME_TAXES

NOTE 12. INCOME TAXES	12 Months Ended
	Sep. 30, 2012
Income Tax Disclosure [Abstract]	'
NOTE 12. INCOME TAXES	'
	NOTE 12 - INCOME TAXES
	Deferred income taxes result from temporary differences in the recognition of income and expenses for the financial reporting purposes and for tax purposes. The Company has a net operating loss carryforward of approximately $25.5 million available to offset future taxable income through 2030. For income tax reporting purposes, the Company’s aggregate unused net operating losses are subject to limitations of Section 382 of the Internal Revenue Code, as amended. Under the Tax Reform Act of 1986, the benefits from net operating losses carried forward may be impaired or limited on certain circumstances. Events which may cause limitations in the amount of net operating losses that the Company may utilize in any one year include, but are not limited to, a cumulative ownership change of more than 50% over a three-year period. The consolidation of any limitations that may be imposed for future issuances of equity securities, including issuances with respect to acquisitions have not been determined. The Company has provided a valuation reserve against the full amount of the net operating loss benefit, because in the opinion of management based upon the earning history of the Company; it is more likely than not that the benefits will not be realized.
	The Company anticipates it will continue to record a valuation allowance against the losses of certain jurisdictions, primarily federal and state, until such time as it is able to determine it is “more-likely-than-not” the deferred tax asset will be realized. Such position is dependent on whether there will be sufficient future taxable income to realize such deferred tax assets. The Company’s effective tax rate may vary from period to period based on changes in estimated taxable income or loss by jurisdiction, changes to the valuation allowance, changes to federal, state or foreign tax laws, future expansion into areas with varying country, state, and local income tax rates, deductibility of certain costs and expenses by jurisdiction.

NOTE_13_SUBSEQUENT_EVENTS

NOTE 13. SUBSEQUENT EVENTS	12 Months Ended
	Sep. 30, 2012
Subsequent Events [Abstract]	'
NOTE 13. SUBSEQUENT EVENTS	'
	NOTE 13– SUBSEQUENT EVENTS
	On November 21, 2012, the Company, through a purchase agreement with CipherSmith, LLC, purchased a complete source code, intellectual property rights, all computer software or algorithm licensed or sold under CipherSmith, and appropriate copy rights, patents, mask works, trademarks,, service marks, internet domain names or world wide web URS. The fair value of the consideration and the assets acquired is based on the aggregate fair value of the common stock issued in exchange for the software. The total fair value on the date of grant was $15,800.
	On June 22, 2012 the Company entered into an acquisition agreement that ultimately closed on March 16, 2013. The Company acquired Doctors Network of America in Flowood, Mississippi for 500,000 common shares and the acquisition was valued at $10,000. As of September 30, 2012, 200,000 shares were issued which were valued at $4,000 and recorded as a deposit on the acquisition. The fair value of the consideration and the assets acquired is based on the aggregate fair value of the common stock issued in exchange for the software. The total fair value on the date of grant was $10,000.
	Immediately after the transaction was closed on March 15, 2013, the sellers refused to pay for medical billing process transaction fees in accordance with their contracts which was approximately $200,000. The Company and the sellers are currently in litigation over the disputed transaction fees of $200,000. The Company has recorded an additional impairment of the acquired asset in the amount of $4,000 for 2012 and $6,000 for 2013.
	In October, 2013, the Company through a purchase agreement with Antree Systems Limited has purchased a complete source code, intellectual property rights, all computer software, patents, or formulas, algorithm licensed or sold under a project known as Compass Rose and appropriate copyrights, patents, mask works, trademarks,, service marks, internet domain names and world wide web URS. The fair value of the consideration and the assets acquired is based on the fair value of the common stock issued in exchange for the software. The total fair value on the date of grant was $6,000.
	In November 2013, the Company entered into a revolving line of credit with Mutual of Omaha for a line of credit in the amount of $65,000 at 4.00% interest rate which renews annually. As of January 10, 2014 we have borrowed $36,500.
	On December 17, 2013 the Company amended its Articles of Incorporation that gave the right to the holders of Preferred A shares to convert 1 share of Convertible Preferred A shares to 150 Common Shares of the Company. The holders of the Preferred A shares can convert the shares upon proper notice to the Board of Directors. Presently the holders of the Preferred A shares have not sent notice to the Board of Directors.
	Stock issuances
	Fiscal Year Ended September 30, 2014
	In October 2013, the Company issued 25,000 shares of common stock for cash of $5,000.
	In October 2013, the Company issued 160,000 shares of common stock to Antree Systems Ltd and 40,000 shares of common stock to Michael Anthony in accordance with the Asset Purchase Agreement. These shares were valued at $6,000 based on the market price on the date of grant.
	In November 2013, the Company issued 180,000 shares of common stock as replacement shares for the 160,000 shares of common stock issued to Antree Systems Ltd and 20,000 shares of common stock to Kimberly Ilicerl. The Company intends to cancel these replacement shares because the shares were lost when delivered to Antree Systems. The Company replaced those lost shares and will cancel the shares that were lost when delivered to Ireland the office of Antree Systems.
	Fiscal Year Ended September 30, 2013
	During year ended September 30, 2013 the Company issued 217,500 shares of common stock for $143,000 in net proceeds as follows:
	Date			Number of Shares		Value
		October 14, 2012			20,000	$	20,000
		October 14, 2012			15,000	$	3,000
		October 14, 2012			18,750	$	2,500
		October 14, 2012			18,750	$	2,500
		December 6, 2012			15,000	$	3,000
		March 12, 2013			20,000	$	20,000
		March 12, 2013			20,000	$	20,000
		April 17, 2013			20,000	$	20,000
		August 26, 2013			20,000	$	2,000
	In October 2012, the Company issued 50,000 shares of common stock valued at $1,300 based on the market price on the date of grant, in conjunction with the sale of medical software. The Company also issued 10,000 shares of common stock valued at $260 based on the market price on the date of grant, as commission payments to the Krooss Family Trust LLP.
	On December 6, 2012, the Company issued 100,000 shares of common stock valued at $2,800 based on the market price on the date of grant, for the sale of medical software and 100,000 shares of common stock valued at $2,800 based on the market price on the date of grant for consulting services.
	On March 12, 2013, the Company issued 50,000 shares of common stock valued at $1,750 based on the market price on the date of grant, for the sale of medical software and 50,000 shares of common stock valued at $1,750 based on the market price on the date of grant for consulting services.
	On March 21, 2013, the Company issued 100,000 shares of common stock valued at $3,500 based on the market price on the date of grant, for the purchase of software in the company in accordance with the Software Licensing and Subscription Agreements.
	On March 21, 2013, the Company issued 667,000 shares of common stock valued at $23,345 based on the market price on the date of grant, to Krooss Family Trust LLP for compensation for the salaries for the entire year of 2013.
	On April 17, 2013, the Company issued 300,000 shares of common stock valued at $6,000 based on the market price on the date of grant, to Krooss Family Trust LLP for the acquisition of Doctors Network of America in Flowood, Mississippi and all of the assets of that company. On April 17, 2013 the Company issued 78,500 to Krooss Family Trust LLP for compensation in accordance with the DNA acquisition agreement and the shares of common stock valued at $2,630 based on the market price on the date of grant, for the software investment in the Company in accordance with the Software Licensing and Subscription Agreements.
	On April 17, 2013, the Company issued 75,000 shares of common stock valued at $2,513 based on the market price on the date of grant, for the software investment in the Company in accordance with the Software Licensing and Subscription Agreements.
	On May 1, 2013, the Company issued 20,000 shares of common stock valued at $522 based on the market price on the date of grant, for programming consulting services.
	On May 10, 2013, the Company issued 20,000 shares of common stock valued at $522 based on the market price on the date of grant, for programming consulting services.
	On June 26, 2013, the Company issued 25,000 shares of common stock valued at $450 based on the market price on the date of grant, for software investment in the Company in accordance with the Software Licensing and Subscription Agreements.
	On August 26, 2013, the Company issued 100,000 shares of common stock valued at $1,800 based on the market price on the date of grant, to two software sales personnel located in California.
	On September 30, 2013, the Company issued 120,000 shares of common stock valued at $3,000 based on the market price on the date of grant, for programming consulting services.
	On September 30, 2013, the Company issued 50,000 shares of common stock valued at $1,250 based on the market price on the date of grant, for software investment in the company in accordance with the Software Licensing and Subscription Agreements.
	During year ended September 30, 2013, the Company issued 500,004 shares of common stock for the acquisition of CipherSmith software. Those shares were valued at $15,800 based on the market price on the dates of grant.
	Employment Agreements
	The Company entered into an employment agreement with its Chief Executive Officer on January 1, 2013.  The employment agreement will expire on January 1, 2018 and shall automatically renew for another 5 years unless terminated in accordance with the provisions of the employment agreement. The employment agreement provides for:
	i.		A monthly salary of $20,833 subject to an annual increase of 10% and consistent with the Company policy applicable to other senior executives and officers and approval by the Board of Directors.
	ii.		A cash bonus of 25% of his annual base salary each year if the Company reaches the following milestones (none of which were attained in 2013):
	a.		The Company posts annual gross revenues on a consolidated basis of at least $5,000,000;
	b.		The Company's earnings before the deduction of income taxes and amortization expenses (“EBITA”), including cash extraordinary items but before officer's bonuses, on a consolidated basis for any year is at least $1,000,000; or the completion of the delinquent SEC filings for five (5) years through September 30, 2013 or the Company obtains FINRA approval for any reverse stock splits.
	iii.		The issuance of shares equal to 1% of the then issued and outstanding shares of the Company annually, which will be issued in 2013.
	iv.		The issuance of common stock on each anniversary date of the employment agreement of 5,000,000 shares and issuance of common stock for every acquisition granting 5,000,000 shares for DNA, 5,000,000 shares for CipherSmith, LLC, and 1,000,000 shares for MediSouth, LLC.
	v.		An automobile allowance of $1,500 per month.
	vi.		A medical insurance allowance of $1,500 per month.
	vii.		In the event the Executive's employment is terminated without cause, he will receive the entire contract remaining on the agreement.
	The Company entered into an employment agreement with its Chief Financial Officer on January 1, 2013.  The employment agreement will expire January 1, 2018 and shall automatically renew for another 5 years unless terminated in accordance with the provisions of the employment agreement. The employment agreement provides for:
	i.		A monthly salary of $12,500 per month subject to an annual increase of 10% per year and consistent with the Company policy applicable to other senior executives and officers and approval by the Board of Directors.
	ii.		A cash bonus of 25% of his annual base salary each year if the Company reaches the following milestones (none of which were attained in 2013):
	a.		The Company posts annual gross revenues on a consolidated basis of at least $5,000,000;
	b.		The Company's EBITA, including cash extraordinary items but before officer's bonuses, on a consolidated basis for any year is at least $1,000,000; or the completion of the delinquent SEC filings for five (5) years through September 30, 2013 or the Company obtains FINRA approval for any reverse stock splits.
	iii.		The issuance of shares equal to 1% of the then issued and outstanding shares of the Company annually, which will be issued in 2013.
	iv.		The issuance of common stock on each anniversary date of the employment agreement of 5,000,000 shares and issuance of common stock for every acquisition granting 3,000,000 shares for DNA, 3,000,000 shares for CipherSmith, LLC, and 750,000 shares for MediSouth, LLC.
	v.		An automobile allowance of $1,000 per month.
	vi.		A medical insurance allowance of $1,500 per month.
	vii.		In the event the Executive's employment is terminated without cause he will receive the entire contract remaining on the agreement.

NOTE_4_SUMMARY_OF_SIGNIFICANT_1

NOTE 4. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)	12 Months Ended
	Sep. 30, 2012
Accounting Policies [Abstract]	'
Use of Estimates and Assumptions	'
	Use of Estimates and Assumptions
	The preparation of financial statements in conformity with accounting principles generally accepted in the United States (“GAAP”) requires management to make estimates and assumptions that affect (i) the reported amounts of assets and liabilities, (ii) the disclosure of contingent assets and liabilities known to exist as of the date the financial statements are published, and (iii) the reported amount of net revenues and expenses recognized during the periods presented. Adjustments made with respect to the use of estimates often relate to improved information not previously available. Uncertainties with respect to such estimates and assumptions are inherent in the preparation of financial statements; accordingly, actual results could differ from these estimates. The Company’s most significant estimates relate to the valuation of its proprietary technology and its valuation of its common stock.
Cash and Cash Equivalents	'
	Cash and Cash Equivalents
	The Company considers all highly liquid investments with an original maturity of three months or less to be cash equivalents.  At September 30, 2012, cash and cash equivalents include cash on hand and cash in the bank and the FDIC insures these deposits up to $250,000.
Impairment of Long-Lived Assets	'
	Impairment of Long-Lived Assets
	The long-lived assets were being evaluated for impairment whenever events or changes in business circumstances indicate that the carrying amount of the assets may not be fully recoverable or that the useful lives of these assets are no longer appropriate. Each impairment test is based on a comparison of the undiscounted future cash flows to the recorded value of the asset. If impairment is indicated, the asset is written down to its estimated fair value. The identifiable intangibles are amortized over their useful lives of 5 years and are reviewed annually for impairment. The Company impaired $4,000 directly related to the acquisition of Doctors Network of America operating in Jackson Mississippi, which is presently in litigation.
Fair Value of Financial Instruments	'
	Fair Value of Financial Instruments
	The Company's financial instruments consist primarily of cash, accounts payable and accrued expenses, and debt. The carrying amounts of such financial instruments approximate their respective estimated fair value due to the short-term maturities and approximate market interest rates of these instruments.
	The Company adopted ASC Topic 820, Fair Value Measurements (“ASC Topic 820”), which defines fair value, establishes a framework for measuring fair value, and expands disclosures about fair value measurements.  The standard provides a consistent definition of fair value which focuses on an exit price that would be received upon sale of an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date.  The standard also prioritizes, within the measurement of fair value, the use of market-based information over entity specific information and establishes a three-level hierarchy for fair value measurements based on the nature of inputs used in the valuation of an asset or liability as of the measurement date.
	The three-level hierarchy for fair value measurements is defined as follows:
	•	Level 1 – inputs to the valuation methodology are quoted prices (unadjusted) for identical assets or liabilities in active markets; liabilities in active markets;
	•	Level 2 – inputs to the valuation methodology include quoted prices for similar assets and liabilities in active markets, and inputs that are observable for the asset or liability other than quoted prices, either directly or indirectly, including inputs in markets that are not considered to be active; or directly or indirectly including inputs in markets that are not considered to be active;
	•	Level 3 – inputs to the valuation methodology are unobservable and significant to the fair value measurement
	The following table summarizes fair value measurements by level at September 30, 2012 and 2011 for assets measured at fair value on a recurring basis:
		Level 1	Level 2	Level 3		Total
	At September 30, 2012
	Proprietary Technology				1,022,591		1,022,591
	Total Proprietary Technology				1,022,591		1,022,591
	At September 30, 2011
	Proprietary Technology				1,200,106		1,200,106
	Total Proprietary Technology				1,200,106		1,200,106
Accounts Receivable and Allowance for Uncollectible Accounts	'
	Accounts Receivable and Allowance for Uncollectible Accounts
	Substantially all of the Company’s accounts receivable balance is related to trade receivables. Trade accounts receivable are recorded at the invoiced amount and do not bear interest. The allowance for doubtful accounts is the Company’s best estimate of the amount of probable credit losses in its existing accounts receivable. The Company will maintain allowances for doubtful accounts for estimated losses resulting from the inability of its customers to make required payments for services. Accounts with known financial issues are first reviewed and specific estimates are recorded. The remaining accounts receivable balances are then grouped in categories by the number of days the balance is past due, and the estimated loss is calculated as a percentage of the total category based upon past history. Account balances are charged against the allowance when it is probable the receivable will not be recovered. As of September 30, 2012 and 2011, the Company had no valuation allowance for the Company’s accounts receivable.
Income Taxes	'
	Income Taxes
	The Company utilizes the asset and liability method in accounting for income taxes. Under this method, deferred tax assets and liabilities are recognized for operating loss and tax credit carry-forwards and for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the year in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in the results of operations in the period that includes the enactment date. A valuation allowance is recorded to reduce the carrying amounts of deferred tax assets unless it is more likely than not that the value of such assets will be realized.
	The Company uses the two-step approach to recognizing and measuring uncertain tax positions. The first step is to evaluate the tax position for recognition by determining if the weight of available evidence indicates it is more likely than not, that the position will be sustained on audit, including resolution of related appeals or litigation processes, if any. The second step is to measure the tax benefit as the largest amount, which is more than 50% likely of being realized upon ultimate settlement. The Company considers many factors when evaluating and estimating the Company's tax positions and tax benefits, which may require periodic adjustments. At September 30, 2012, the Company did not record any liabilities for uncertain tax positions.
Revenue Recognition	'
	Revenue Recognition
	License revenue consists principally of revenue earned under software license agreements. The Company sells its software to a medical practitioner for direct payment or through a third party leasing company for direct payment to the Company. The third party lease agreement is a non-recourse debt and the Company is not responsible for the default of the medical practitioner. License revenue is generally recognized when a signed contract or other persuasive evidence of an arrangement exists, the software has been electronically delivered, the license fee is fixed or is measured on a paid user basis; and collection of the resulting receivable is probable. When contracts contain multiple elements wherein Vendor-Specific Objective Evidence (“VSOE”) exists for all undelivered elements, we account for the delivered elements in accordance with the “Residual Method.” VSOE of fair value for maintenance and support is established by a stated renewal rate, if substantive, included in the license arrangement or rates charged in stand-alone sales of maintenance and support. Revenue from subscription license agreements, which include software, rights to unspecified future products and maintenance, is recognized ratably over the term of the subscription period.
	Provided all other revenue criteria are met, the upfront, minimum, non-refundable license fees from customers are generally recognized upon delivery and on-going royalty fees are generally recognized upon reports of new licenses issued. If there is significant uncertainty about the project completion or receipt of payment for professional services, revenue is deferred until the uncertainty is sufficiently resolved. VSOE of fair value of services is based upon stand-alone sales of those services.
	Subscription revenue is generated from bandwidth and information storage. One year and each year thereafter the software is purchased and installed the purchaser will pay an annual fee of $1,200, $1,500, $1,800, and $2,400, respectively. Subscription revenue is recognized ratably over the term of the agreement.
	Transaction revenue is generated from the following services and recognized when transaction occurs:
	·	Electronic Remittance Advise $0.35 Electronic remittance transaction fee;
	·	Paper Claims $1.00 Paper claim fee;
	·	Carrier Direct $0.16 Carrier direct fee;
	·	Fast Forward $0.35 Fast forward transaction fee; and,
	·	Patient Credit $2.50 Automatic Debit processing per transaction paid by the patient
	The Company has not incurred any transaction revenues in the year ended September 30, 2012.
Cost of License and Subscriptions Revenues	'
	Cost of License, and Subscriptions Revenues
	Cost of license revenue is primarily comprised of the license-based royalties to third parties and production and distribution costs for initial product licenses.
	Cost of subscription revenue is primarily comprised of the costs associated with the customer support personnel that provide maintenance, enhancement and support services to customers.
	The amortization of acquired technology for products acquired through business combinations are considered as the cost of revenues.
Sales Commissions	'
	Sales Commissions
	The Company pays commissions, including sales bonuses, to the direct sales force related to revenue transactions under sales compensation plans established annually. The commission payments are typically paid in full in the month or quarter following execution of the customer contracts. The Company paid commissions of $73,298 and $0 for the years ended September 30, 2012 and 2011, respectively.
Research and Development and Software Development Costs	'
	Research and Development and Software Development Costs
	Capitalization of certain software development costs subsequent to the establishment of technological feasibility. Based on our product development process, technological feasibility is established upon the completion of a working model. To date, costs incurred by us from the completion of the working model to the point at which the product is ready for general release have been insignificant. Accordingly, we have charged all such costs to research and development expense in the period incurred. Our research and development costs for the years ended September 30, 2012 and 2011 were $151,000 and $93,871, respectively.
Share-Based Compensation	'
	Share-Based Compensation
	The Company measures the cost of services received in exchange for an award of an equity instrument based on the grant-date fair value of the award.  Compensation cost is recognized over the vesting or requisite service period.
Basic and Diluted Net Loss per Common Share	'
	Basic and Diluted Net Loss per Common Share
	Basic income (loss) per share is computed by dividing net income (loss) available to common shareholders by the weighted average number of common shares outstanding during the reporting period. The weighted average number of shares is calculated by taking the number of shares outstanding and weighting them by the amount of time that they were outstanding.  Diluted earnings per share reflects the potential dilution that could occur if stock options, warrants, and other commitments to issue common stock were exercised or equity awards vest resulting in the issuance of common stock that could share in the earnings of the Company. As of September 30, 2012 and 2011, the Company had no potentially dilutive instruments outstanding.
	Diluted loss per share is the same as basic loss per share during periods where net losses are incurred since the inclusion of the potential common stock equivalents would be anti-dilutive as a result of the net loss.
Concentration of Credit Risk	'
	Concentration of Credit Risk
	All of the Company’s cash and cash equivalents are maintained in regional and national financial institutions. The Company has exposure to credit risk to the extent that its cash and cash equivalents exceed amounts covered by the U.S. federal deposit insurance; however, the Company has not experienced any losses in such accounts. In management’s opinion, the capitalization and operating history of the financial institutions are such that the likelihood of material loss is remote.
Reclassifications	'
	Reclassifications
	Certain prior period amounts have been reclassified to conform to the current year presentation.
Subsequent Events	'
	Subsequent Events
	The Company has evaluated all transactions occurring between the end of its fiscal year, September 30, 2012, through the date of issuance of the financial statements for subsequent event disclosure consideration.
Recent Accounting Pronouncements	'
	Recent Accounting Pronouncements
	No accounting standards or interpretations issued recently are expected to a have a material impact on the Company’s financial position, operations or cash flows.

NOTE_4_SUMMARY_OF_SIGNIFICANT_2

NOTE 4. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)	12 Months Ended
	Sep. 30, 2012
Accounting Policies [Abstract]	'
Fair Value Assets Measured on Recurring Basis	'
		Level 1	Level 2	Level 3		Total
	At September 30, 2012
	Proprietary Technology				1,022,591		1,022,591
	Total Proprietary Technology				1,022,591		1,022,591
	At September 30, 2011
	Proprietary Technology				1,200,106		1,200,106
	Total Proprietary Technology				1,200,106		1,200,106

NOTE_5_INTANGIBLE_ASSETS_Table

NOTE 5. INTANGIBLE ASSETS (Tables)	12 Months Ended
	Sep. 30, 2012
Goodwill and Intangible Assets Disclosure [Abstract]	'
Intangible Assets	'
		2012			2011
	Source Code License	$	2,500		$	—
	Software License		1,200,106			1,200,106
	Acquisition of Doctor’s Network of America		4,000			—
	Total intangible assets		1,202,606			1,200,106
	Accumulated amortization of intangible assets		(180,015	)		—
	Impairment of assets		(4,000	)		—
	Total intangible assets	$	1,022,591		$	1,200,106
Assets Acquired under Common Control	'
	Cost Basis for assets acquired  under Common Control	Cost Basis
	Cost basis of Consideration:
	Absolute Medical Software Systems LLC development costs from inception	$	1,011,222
	Impairment of software on September 10, 2008 to value		-11,222
	Total Value at September 10, 2008	$	1,000,000
	Software Update to Operate on Cloud Based Platform
	Absolute Medical Software Systems LLC development costs	$	200,106
	Total Cost Basis at January 1, 2011	$	1,200,106

NOTE_6_DISCONTINUED_OPERATIONS1

NOTE 6. DISCONTINUED OPERATIONS (Tables)	12 Months Ended
	Sep. 30, 2012
Discontinued Operations and Disposal Groups [Abstract]	'
Discontinued Operations - Liabilities and Operations	'
		30-Sep-12			September 30,
					2011
	Net liabilities of discontinued operations:
	Accounts payable and accrued expenses	$	—		$	169,176
	Disputed salaries & vacation of former officers		—			968,645
	Disputed salary – former employee		—			20,256
	Disputed payroll taxes for back pay of former officers		—			84,701
	Disputed interest		—			209,215
	Interest expenses		—			42,137
	Former officer note payable at 8% interest rate		—			59,704
	Shareholders demand note payable at 12%		—			11,625
	Shareholders demand note payable at 12%		—			20,000
	Unsecured note payable at 8% interest due November 2010 interest payments in default at 9/30/2009		—			175,000
	Net liabilities of discontinued operations	$	—		$	1,760,459
		Year ended
		September 30,
		2012			2011
	Discontinued operations:
	Revenues	$	—		$	3,400
	Cost of sales		—			—
	Operating expenses		—			—
	Interest expense		(17,868	)		(19,612	)
	Gain from write-off of debt		410,482			—
	Gain (Loss) from Discontinued Operations	$	392,614		$	(16,212	)

NOTE_7_DEBT_MITIGATION_PROGRAM1

NOTE 7. DEBT MITIGATION PROGRAM (Tables)	12 Months Ended
	Sep. 30, 2012
OTHER (INCOME) AND EXPENSES	'
Debt Mitigation Program	'
			30-Sep-12
	Debt Mitigation Program:
	Accounts payable and accrued expenses	$	66,281
	Disputed salaries & vacation of former officers		968,645
	Disputed salary – former employee		20,256
	Disputed payroll taxes for back pay of former officers		84,701
	Disputed interest		227,083
	Shareholders demand note payable at 12%		11,625
	Shareholders demand note payable at 12%		20,000
	Unsecured note payable at 8% interest due in November 2010, interest payments in default		175,000
	Total debt mitigation program	$	1,573,591
	Gain on write off of debt	$	(410,483	)
	Additional paid-in capital (1)	$	(1,163,108	)

NOTE_10_EQUITY_Tables

NOTE 10. EQUITY (Tables)	12 Months Ended
	Sep. 30, 2012
Equity [Abstract]	'
Issuance of Common Stock	'
	Date		Number of Shares		Value
		15-Oct-11		25,000	$	5,000
		29-Dec-11		100,000	$	50,000
		21-Jun-12		65,000	$	13,000

NOTE_11_STOCKBASED_COMPENSATIO1

NOTE 11. STOCK-BASED COMPENSATION (Tables)	12 Months Ended
	Sep. 30, 2012
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]	'
Summary of Warrant Activity	'
			Number of			Weighted		Weighted Average		Aggregate
			Shares Granted			Average		Remaining		Intrinsic Value
						Exercise Price		Contractual Life
								(years)
		30-Sep-10		2,308,497		$	0.1		0.38		—
		Grants		—			—
		Expired		(2,308,497	)		—
		30-Sep-11		—		$	—	$	—	$	—
		Grants		—
		Expired		—
		30-Sep-12		—		$	—	$	—	$	—

NOTE_13_SUBSEQUENT_EVENTS_Tabl

NOTE 13. SUBSEQUENT EVENTS (Tables)	12 Months Ended
	Sep. 30, 2012
Subsequent Events [Abstract]	'
Shares Issued in Year Ended September 30, 2013	'
	Date		Number of Shares		Value
		October 14, 2012		20,000	$	20,000
		October 14, 2012		15,000	$	3,000
		October 14, 2012		18,750	$	2,500
		October 14, 2012		18,750	$	2,500
		December 6, 2012		15,000	$	3,000
		March 12, 2013		20,000	$	20,000
		March 12, 2013		20,000	$	20,000
		April 17, 2013		20,000	$	20,000
		August 26, 2013		20,000	$	2,000

NOTE_3_GOING_CONCERN_ISSUES_De

NOTE 3. GOING CONCERN ISSUES (Details Narrative) (USD $)	Sep. 30, 2012	Sep. 30, 2011
Organization, Consolidation and Presentation of Financial Statements [Abstract]	'	'
Accumulated Deficit	($25,911,091)	($26,229,970)

NOTE_4_SUMMARY_OF_SIGNIFICANT_3

NOTE 4. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Fair Value Assets Measured on Recurring Basis (Details) (USD $)	Sep. 30, 2012	Sep. 30, 2011
Proprietary Technology	$1,022,591	$1,200,106
Total Proprietary Technology	1,022,591	1,200,106
Level 3	'	'
Proprietary Technology	1,022,591	1,200,106
Total Proprietary Technology	$1,022,591	$1,200,106

NOTE_4_SUMMARY_OF_SIGNIFICANT_4

NOTE 4. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative) (USD $)	12 Months Ended
	Sep. 30, 2012	Sep. 30, 2011	Mar. 30, 2012	Mar. 30, 2011
Accounting Policies [Abstract]	'	'	'	'
FDIC Insured Cash	'	'	$250,000	'
Intangible Assets, Impaired	4,000	'	'	'
Subscription Revenue in Year One	1,200	'	'	'
Subscription Revenue in Year Two	1,500	'	'	'
Subscription Revenue in Year Three	1,800	'	'	'
Subscription Revenue in Year Four	2,400	'	'	'
Commissions	'	'	73,298	0
Research and Development Costs	$151,000	$93,871	'	'

NOTE_5_INTANGIBLE_ASSETS_Intan

NOTE 5. INTANGIBLE ASSETS - Intangible Assets (Details) (USD $)	Oct. 31, 2013	Nov. 21, 2012	Sep. 30, 2012	Sep. 30, 2011
Goodwill and Intangible Assets Disclosure [Abstract]	'	'	'	'
Source Code License	'	'	$2,500	'
Software License	'	'	1,200,106	1,200,106
Acquisition of Doctors Network of America	6,000	15,800	4,000	'
Total intangible assets	'	'	1,206,606	1,200,106
Accumulated amortization of intangible assets	'	'	-180,015	'
Impairment of assets	'	'	-4,000	'
Total intangible assets	'	'	$1,022,591	$1,200,106

NOTE_5_INTANGIBLE_ASSETS_Asset

NOTE 5. INTANGIBLE ASSETS - Assets Acquired under Common Control (Details) (USD $)	12 Months Ended
	Sep. 30, 2012
Goodwill and Intangible Assets Disclosure [Abstract]	'
Absolute Medical Software Systems LLC development costs from inception	$1,011,222
Impairment of software on September 10, 2008 to value	-11,222
Total Value at September 10, 2008	1,000,000
Absolute Medical Software Systems LLC development costs	200,106
Total Cost Basis at January 1, 2011	$1,200,106

NOTE_5_INTANGIBLE_ASSETS_Detai

NOTE 5. INTANGIBLE ASSETS (Details Narrative) (USD $)	1 Months Ended	3 Months Ended	12 Months Ended
	Jun. 30, 2012	Dec. 31, 2013	Sep. 30, 2013	Sep. 30, 2012	Sep. 30, 2011	Jan. 02, 2011	Sep. 30, 2007	31-May-06	Apr. 27, 2006	Nov. 01, 2005	27-May-05
Impairment of Long-Lived Assets	'	'	'	$4,000	'	'	'	'	'	'	'
Amortization Expense	'	'	'	180,015	'	'	'	'	'	'	'
Stock Issued During Period for Purchase of Assets, Shares	'	'	500,004	100,000	'	'	'	'	'	'	'
Fair Value of Consideration and Assets Acquired	'	'	'	2,500	'	'	'	'	'	'	'
Convertible Promissory Note Issued	'	'	'	'	'	1,200,106	'	'	'	'	'
Convertible Note Payable, Interest Rate	'	'	'	'	'	8.00%	8.00%	1200.00%	1200.00%	800.00%	6.00%
Stock Issued During Period for Settlement of Debt, Shares	'	30,000,000	'	30,000,000	'	'	'	'	'	'	'
Shares Issued, Price Per Share	'	'	'	$0.01	$0.01	'	'	'	'	$0.04	'
Shares Issued in Acquisition, Shares	500,000	'	'	10,000	'	'	'	'	'	'	'
Stock Issued for Acquisitions, Value	10,000	'	'	200,000	'	'	'	'	'	'	'
Commitments [Member]	'	'	'	'	'	'	'	'	'	'	'
Shares Issued in Acquisition, Shares	'	'	'	500,000	'	'	'	'	'	'	'
Stock Issued for Acquisitions, Value	'	'	'	$4,000	'	'	'	'	'	'	'
Deposits [Member]	'	'	'	'	'	'	'	'	'	'	'
Shares Issued in Acquisition, Shares	'	'	'	200,000	'	'	'	'	'	'	'

NOTE_6_DISCONTINUED_OPERATIONS2

NOTE 6. DISCONTINUED OPERATIONS - Discontinued Operations - Liabilities and Operations (Details) (USD $)	12 Months Ended
	Sep. 30, 2012	Sep. 30, 2011	31-May-06	Apr. 27, 2006	Nov. 01, 2005
Note Payable	'	'	$20,000	$16,625	$175,000
Revenues	487,703	'	'	'	'
Cost of sales	181,739	'	'	'	'
Operating expenses	378,211	340,417	'	'	'
Interest expense	1,488	'	'	'	'
Gain from write-off of debt	-410,483	'	'	'	'
Former Office Note	'	'	'	'	'
Note Payable	'	59,704	'	'	'
Shareholders Demand Note 1	'	'	'	'	'
Note Payable	'	11,625	'	'	'
Shareholders Demand Note 2	'	'	'	'	'
Note Payable	'	20,000	'	'	'
Unsecured Note	'	'	'	'	'
Note Payable	'	175,000	'	'	'
Discontinued Operations [Member]	'	'	'	'	'
Accounts payable and accrued expenses	'	169,176	'	'	'
Disputed salaries & vacation of former officers	'	968,645	'	'	'
Disputed salary - former employee	'	20,256	'	'	'
Disputed payroll taxes for back pay of former officers	'	84,701	'	'	'
Disputed interest	'	209,215	'	'	'
Interest expenses	'	42,137	'	'	'
Net liabilities of discontinued operations	'	1,760,459	'	'	'
Revenues	'	3,400	'	'	'
Cost of sales	'	'	'	'	'
Operating expenses	'	'	'	'	'
Interest expense	-17,868	-19,612	'	'	'
Gain from write-off of debt	410,482	'	'	'	'
Gain (Loss) from Discontinued Operations	$392,614	($16,212)	'	'	'

NOTE_6_DISCONTINUED_OPERATIONS3

NOTE 6. DISCONTINUED OPERATIONS (Details Narrative) (USD $)	3 Months Ended	12 Months Ended
	Sep. 30, 2007	Sep. 30, 2012	Sep. 30, 2011	Sep. 30, 2006	Sep. 30, 2005	Jan. 02, 2011	31-May-06	Apr. 27, 2006	Nov. 01, 2005	27-May-05
Discontinued Operations and Disposal Groups [Abstract]	'	'	'	'	'	'	'	'	'	'
Sale of Assets, Purchase Price	'	'	$100,000	'	'	'	'	'	'	'
Note Payable	'	'	'	'	'	'	20,000	16,625	175,000	'
Note Payable, Interest Rate	8.00%	'	'	'	'	8.00%	1200.00%	1200.00%	800.00%	6.00%
Shares Issued, Financing Program	'	'	'	'	1,200,000	'	'	'	'	'
Per Share Conversion Price	'	'	'	'	'	'	'	'	$0.05	'
Shares Issued, Price Per Share	'	$0.01	$0.01	'	'	'	'	'	$0.04	'
Debt Discount	'	'	'	'	'	'	'	'	51,600	'
Beneficial Conversion Feature	'	'	'	'	9,933	'	'	'	'	'
Deferred Financing Costs, Issuance of Shares	'	'	'	'	'	'	'	'	24,000	'
Related Party Payable	13,300	25,591	180,796	'	'	'	'	'	'	159,000
Proceeds from Repayment of Related Party Debt	11,000	188,410	0	'	'	'	'	'	'	'
Due to Related Party	148,000	'	'	'	'	'	'	'	'	'
Interest Payable	13,300	'	'	'	'	'	'	'	'	'
Origination/Placement Fee	'	'	'	500	'	'	'	'	'	'
Warrants Issued	'	'	'	$100,000	'	'	'	'	'	'
Purchase Price Per Share	'	'	'	'	'	'	$0.04	$0.04	'	'

NOTE_7_DEBT_MITIGATION_PROGRAM2

NOTE 7. DEBT MITIGATION PROGRAM - Debt Mitigation Program (Details) (USD $)	12 Months Ended
	Sep. 30, 2012
Debt mitigation program	$1,573,591
Gain on write off of debt	-410,483
Additional paid-in capital	1,163,109	[1]
Accounts Payable and Accrued Expenses	'
Debt mitigation program	66,281
Disputed Salaries & Vacations of Former Officers	'
Debt mitigation program	968,645
Disputed Salaries of Former Employees	'
Debt mitigation program	20,256
Disputed Payroll Taxes for Back Pay of Former Officers	'
Debt mitigation program	84,701
Disputed Interest	'
Debt mitigation program	227,083
Shareholders Demand Note 1	'
Debt mitigation program	11,625
Shareholders Demand Note 2	'
Debt mitigation program	20,000
Unsecured Note	'
Debt mitigation program	$175,000
[1]	All amounts that were owed to related parties in prior years were recorded to paid-in-capital.

NOTE_7_DEBT_MITIGATION_PROGRAM3

NOTE 7. DEBT MITIGATION PROGRAM (Details Narrative) (USD $)	12 Months Ended
	Sep. 30, 2012
OTHER (INCOME) AND EXPENSES	'
Creditor Liabilities, Write Off	$1,573,591
Gain on the Write Off of Liabilities	410,482
Additional Paid-In Capital for Related Party Liabilities	$1,163,109	[1]
[1]	All amounts that were owed to related parties in prior years were recorded to paid-in-capital.

NOTE_8_COMMITMENT_AND_CONTINGE1

NOTE 8. COMMITMENT AND CONTINGENCIES (Details Narrative) (USD $)	12 Months Ended
	Sep. 30, 2012	Sep. 30, 2011
COMMITMENTS AND CONTINGENCIES	'	'
Rent Expense	$0	$0
Litigation Reserve	200,000	'
Write Offs	$1,573,591	'

NOTE_9_RELATED_PARTY_TRANSACTI1

NOTE 9. RELATED PARTY TRANSACTIONS (Details Narrative) (USD $)	1 Months Ended	3 Months Ended		12 Months Ended
	Apr. 30, 2011	Dec. 31, 2013	Sep. 30, 2007	Sep. 30, 2012	Sep. 30, 2011	27-May-05
Stock Issued to Management, Shares	4,000,000	'	'	'	'	'
Trading Price Per Share	$0.01	'	'	'	$0.01	'
Stock Issued During Period to New Management, Value	$38,000	'	'	$624	$143,000	'
Stock Issued for Conversion of Debt, Shares	'	30,000,000	'	30,000,000	'	'
Stock Issued, Conversion of Debt, Value	'	1,200,106	'	1,200,106	'	'
Due to Related Party	'	'	'	7,969	159,515	'
Due to Related Party, Other	'	'	'	25,236	'	'
Repayments of Related Party Debt	'	'	11,000	188,410	0	'
Due to Related Parties	'	'	13,300	25,591	180,796	159,000
Common Stock	'	'	'	'	'	'
Stock Issued to Management, Shares	'	'	'	'	15,000,000	'
Stock Issued During Period to New Management, Value	'	'	'	'	150,000	'
Stock Issued for Conversion of Debt, Shares	'	'	'	30,000,000	'	'
Stock Issued, Conversion of Debt, Value	'	'	'	$300,000	'	'

NOTE_10_EQUITY_Issuance_of_Com

NOTE 10. EQUITY - Issuance of Common Stock (Details) (USD $)	Sep. 30, 2012	Jun. 21, 2012	Dec. 29, 2011	Oct. 15, 2011
Equity [Abstract]	'	'	'	'
Number of Shares	200,000	65,000	100,000	25,000
Value	'	$13,000	$50,000	$5,000

NOTE_10_EQUITY_Details_Narrati

NOTE 10. EQUITY (Details Narrative) (USD $)

1 Months Ended

12 Months Ended

12 Months Ended

Dec. 31, 2013

Sep. 30, 2013

Sep. 30, 2012

Sep. 30, 2011

Sep. 09, 2012

Dec. 15, 2011

Oct. 15, 2011

Apr. 11, 2011

Jan. 02, 2011

Nov. 01, 2005

Sep. 30, 2012

Sep. 30, 2012

Jun. 21, 2012

Jun. 21, 2012

Medical Billing Software [Member]

Acquisition-related Costs [Member]

Acquisition-related Costs [Member]

Goods and Services Exchanged for Equity Instrument [Member]

Common Stock Shares Authorized

'

'

650,000,000

650,000,000

'

'

'

650,000,000

'

'

'

'

'

'

Preferred Stock Shares Authorized

'

'

4,000,000

4,000,000

'

'

'

4,000,000

'

'

'

'

'

'

Preferred Stock Par Value

'

'

$0.01

$0.01

'

'

'

$0.01

'

'

'

'

'

$0.02

Common Stock, Shares Issued

'

'

211,991,212

180,526,879

14,000

18,000

30,000,000

'

15,000,000

'

941,333

100,000

200,000

1,000

Common Stock, Shares Issued, Value

'

'

$2,119,912

$1,805,269

$420

'

$1,200,106

'

$105,000

'

'

$2,500

$4,000

$20

Common Stock, Shares Issued, Value

'

'

$0.01

$0.01

$0.03

$0.01

'

'

$0.01

'

'

$0.03

$0.02

'

Consulting Fees

'

'

184

'

'

'

'

'

'

'

'

'

'

'

Common Stock, Market Price, Minimum

'

'

'

'

'

'

'

'

'

'

$0.01

'

'

'

Common Stock, Market Price, Maximum

'

'

'

'

'

'

'

'

'

'

$0.03

'

'

'

Reduction to Revenue

'

'

'

'

'

'

'

'

'

'

19,301

'

'

'

Sale of Stock, Shares Sold

'

'

'

250,000

'

'

'

'

'

'

'

'

'

'

Sale of Stock, Consideration Received

'

'

'

25,000

'

'

'

'

'

'

'

'

'

'

Preferred Stock, Share Reservation

'

'

'

4,000,000

'

'

'

'

'

'

'

'

'

'

Preferred Stock, Voting Rights

'150

'

'

'150

'

'

'

'

'

'

'

'

'

'

Preferred Stock, Shares Issued

'

'

4,000,000

4,000,000

'

'

'

'

'

'

'

'

'

'

Compensation Expense

'

'

'

38,000

'

'

'

'

'

'

'

'

'

'

Shares Issued In Period

'

217,500

190,000

'

'

'

'

'

'

'

'

'

'

'

Shares Issued In Period, Value

'

$143,000

$68,000

'

'

'

'

'

'

'

'

'

'

'

Shares Issued, Price Per Share

'

'

$0.01

$0.01

'

'

'

'

'

$0.04

'

'

'

'

NOTE_11_STOCKBASED_COMPENSATIO2

NOTE 11. STOCK-BASED COMPENSATION - Summary of Warrant Activity (Details) (USD $)	12 Months Ended
	Sep. 30, 2012	Sep. 30, 2011
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]	'	'
Shares Granted	'	2,308,497
Weighted Average Exercise Price	'	$0.10
Weighted Average Remaining Contractual Life	'0 months	'4 months
Aggregate Intrinsic Value	'	'
Grants	'	'
Grants, Per Share	'	'
Expired	'	-2,308,497
Expired, Per Share	'	'

NOTE_12_INCOME_TAXES_Details_N

NOTE 12. INCOME TAXES (Details Narrative) (USD $)	Sep. 30, 2012
Income Tax Disclosure [Abstract]	'
Net Operating Loss Carryforward	$25,500,000

NOTE_13_SUBSEQUENT_EVENTS_Shar

NOTE 13. SUBSEQUENT EVENTS - Shares Issued in Year Ended September 30, 2013 (Details) (USD $)	Sep. 30, 2012	Jun. 21, 2012	Dec. 29, 2011	Oct. 15, 2011	Aug. 26, 2013	Apr. 17, 2013	Mar. 12, 2013	Dec. 06, 2012	Oct. 14, 2012	Mar. 12, 2013	Oct. 14, 2012	Oct. 14, 2012	Oct. 14, 2012
					Equity Issuance A	Equity Issuance A	Equity Issuance A	Equity Issuance A	Equity Issuance A	Equity Issuance B	Equity Issuance B	Equity Issuance C	Equity Issuance D
Number of Shares	200,000	65,000	100,000	25,000	20,000	20,000	20,000	15,000	20,000	20,000	15,000	18,750	18,750
Value	'	$13,000	$50,000	$5,000	$2,000	$20,000	$20,000	$3,000	$20,000	$20,000	$3,000	$2,500	$2,500

NOTE_13_SUBSEQUENT_EVENTS_Deta

NOTE 13. SUBSEQUENT EVENTS (Details Narrative) (USD $)

0 Months Ended

1 Months Ended

12 Months Ended

9-May-13

Mar. 21, 2013

Mar. 12, 2013

Dec. 31, 2013

Nov. 30, 2013

Oct. 31, 2013

Sep. 30, 2013

Aug. 31, 2013

Jun. 30, 2013

31-May-13

Apr. 30, 2013

Dec. 31, 2012

Oct. 31, 2012

Jun. 30, 2012

Sep. 30, 2013

Sep. 30, 2012

Sep. 30, 2011

Jan. 10, 2014

Nov. 21, 2012

Jun. 21, 2012

Dec. 29, 2011

Oct. 15, 2011

Acquisition of Software, Fair Value

'

'

'

'

'

$6,000

'

'

'

'

'

'

'

'

'

$4,000

'

'

$15,800

'

'

'

Shares Issued in Acquisition

'

'

'

'

'

'

'

'

'

'

'

'

'

500,000

'

10,000

'

'

'

'

'

'

Stock Issued for Acquisitions, Value

'

'

'

'

'

'

'

'

'

'

'

'

'

10,000

'

200,000

'

'

'

'

'

'

Shares Issued

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

200,000

'

'

'

65,000

100,000

25,000

Shares Issued, Value

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

4,000

'

'

'

'

'

'

Litigation Contingency

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

200,000

'

'

'

'

'

'

Impairment of Acquired Asset

'

'

'

'

'

'

'

'

'

'

'

'

'

'

6,000

4,000

'

'

'

'

'

'

Line of Credit, Amount

'

'

'

'

65,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Line of Credit, Interest Rate

'

'

'

'

4.00%

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Line of Credit, Amount Outstanding

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

36,500

'

'

'

'

Preferred Stock Voting Rights

'

'

'

'150

'

'

'

'

'

'

'

'

'

'

'

'

'150

'

'

'

'

'

Stock Issued for Cash, Shares

'

'

'

'

'

25,000

'

'

'

'

'

'

'

'

'

68,000

25,000

'

'

'

'

'

Stock Issued for Cash, Value

'

'

'

'

'

5,000

'

'

'

'

'

'

'

'

'

68,000

25,000

'

'

'

'

'

Stock Issued, Asset Purchase Agreement, Shares

'

'

'

'

'

'

'

'

'

'

'

'

'

'

500,004

100,000

'

'

'

'

'

'

Stock Issued, Asset Purchase Agreement, Value

'

'

'

'

'

6,000

'

'

'

'

'

'

'

'

15,800

2,500

'

'

'

'

'

'

Stock Issued, Replacement Shares

'

'

'

'

180,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Stock Issued During Period, Shares

'

'

'

'

'

'

'

'

'

'

'

'

'

'

217,500

190,000

'

'

'

'

'

'

Stock Issued During Period, Value

'

'

'

'

'

'

'

'

'

'

'

'

'

'

143,000

68,000

'

'

'

'

'

'

Stock Issued, Sale of Medical Software, Shares

'

100,000

50,000

'

'

'

'

'

'

'

'

100,000

50,000

'

'

'

'

'

'

'

'

'

Stock Issued, Sale of Medical Software, Value

'

3,500

1,750

'

'

'

'

'

'

'

'

2,800

1,300

'

'

'

'

'

'

'

'

'

Stock Issued, Commission Payments, Shares

20,000

667,000

50,000

'

'

'

120,000

100,000

'

20,000

'

100,000

10,000

'

'

'

'

'

'

'

'

'

Stock Issued, Commission Payments, Value

522

23,345

1,750

'

'

'

3,000

1,800

'

522

'

2,800

260

'

'

624

'

'

'

'

'

'

Stock Issued, Software Investment, Shares

'

'

'

'

'

'

50,000

'

25,000

'

75,000

'

'

'

'

'

'

'

'

'

'

'

Stock Issued, Software Investment, Value

'

'

'

'

'

'

1,250

'

450

'

2,513

'

'

'

'

19,301

'

'

'

'

'

'

Doctors Network [Member]

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Shares Issued in Acquisition

'

'

'

'

'

'

'

'

'

'

300,000

'

'

'

'

'

'

'

'

'

'

'

Stock Issued for Acquisitions, Value

'

'

'

'

'

'

'

'

'

'

6,000

'

'

'

'

'

'

'

'

'

'

'

Krooss Family [Member]

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Shares Issued in Acquisition

'

'

'

'

'

'

'

'

'

'

78,500

'

'

'

'

'

'

'

'

'

'

'

Stock Issued for Acquisitions, Value

'

'

'

'

'

'

'

'

'

'

$2,630

'

'

'

'

'

'

'

'

'

'

'

Antree [Member]

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Stock Issued, Asset Purchase Agreement, Shares

'

'

'

'

'

160,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Common Stock, Lost Shares

'

'

'

'

160,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Michael Anthony [Member]

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Stock Issued, Asset Purchase Agreement, Shares

'

'

'

'

'

40,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Kimberly Ilicerl [Member]

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Common Stock, Lost Shares

'

'

'

'

20,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'